The primary study objective was to evaluate the prognostic value of post-therapeutic SPECT by RECIP 1.0 for overall survival.

Q3 2025 Management View CEO Jim Frakes noted that Aethlon Medical has made significant progress in focusing on oncology and implementing cost reductions. Operating expenses were reduced by 50% ...

Older people have greater general happiness, life satisfaction and sense of purpose than they did before the COVID-19 ...